Tiefenbacher Pharmaceuticals successfully launches the anticoagulant Rivaroxaban on day one in Canada.

We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable and available for all patients around the world – irrespective of their nationality or income. That´s why we are thrilled to share that we have successfully prepared a day one launch of the generic version of Rivaroxaban in Canada.

Rivaroxaban is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. The tablets are marketed in the strengths 2.5mg (for the very first time), 10mg, 15mg, and 20mg by our cooperation partner, one of the biggest generic pharmaceutical companies in the world. The product has been developed in TIEFENBACHER GROUP´s own laboratories in Hyderabad, India, and has already been launched in several European and international markets before. Overall, our country scope covers about 70 countries around the world.

This launch is a testament to the hard work and commitment of our team. We are excited about the positive impact this achievement will have, and we look forward to the continued success of Rivaroxaban in the Canadian market.

AET TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes affordable high-quality healthcare solutions as well as medical devices worldwide. We provide over 180+ pharmaceuticals products across various therapeutic categories in 40+ dosage forms. With our in-house product development, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines including high-potent for global markets. 

For more information around our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or please visit us on:www.tiefenbacher-pharmaceuticals.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.